Vanda Pharmaceuticals Inc.
VNDAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The $328.3M market capitalization puts VNDA squarely in small-cap range for its industry. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Market Cap
$328.3M
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
27.15
EPS (TTM)
$-4.64
EPS (Fwd)
$0.20
ROE
-77.8%
ROA
-22.4%
Cash
$170.0M
Total Debt
$22.8M
Free CF
-$86.7M
52W Change
19.3%
Annual Financials
Cash vs Debt
Where VNDA stands vs its 150-day and 200-day moving averages
As of the August 17, 2026 close, VNDA finished 22.55% below its 150-day moving average ($6.74) and 19.82% below its 200-day moving average ($6.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VNDA overbought or oversold?
At the August 17, 2026 close, VNDA's RSI(14) was 50.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $170.0M in cash comfortably exceeding the $22.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$86.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -77.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $254.4M to $216.1M.
The relatively low beta of 0.65 suggests VNDA is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, VNDA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Vanda Pharmaceuticals Inc. and its sector.